-

SHAREHOLDER ALERT: Robbins LLP Informs Investors that Alfi, Inc. (ALF, ALFIW) is Being Sued for Misleading Investors

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased Alfi, Inc. (NASDAQ: ALF, ALFIW) common stock or warrants pursuant to the Company's May 4, 2021 initial public offering ("IPO") or securities between May 4, 2021 and November 15, 2021. The complaint alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934. Alfi provides interactive artificial intelligence and machine learning software solutions.

If you suffered a loss due to Alfi, Inc.'s misconduct, click here.

Alfi, Inc. (ALF, ALFIW) Failed to Disclose Deficient Disclosure Controls and Internal Control over Financial Reporting

According to the complaint, Afli began trading publicly on May 4, 2021. However, the documents filed in support of the IPO (the "Offering Documents") were negligently prepared. Specifically, the Offering Documents failed to disclose that Alfi maintained deficient disclosure controls and procedures and internal control over financial reporting. As a result, the Company and its employees could and did engage in corporate transactions and other matters without sufficient and appropriate consultation with or approval by the Company’s Board of Directors. This increased the risk of internal and regulatory investigations into the Company and its employees.

On October 28, 2021, Alfi disclosed that the Board had placed the Company's Chief Executive Officer, Chief Technology Officer, and Chief Financial Officer "on paid administrative leave and authorized an independent internal investigation regarding certain corporate transactions and other matters," and had subsequently terminated its Chief Technology Officer. Then, on November 1, 2021, Alfi disclosed its Chair of the Audit Committee had resigned from the Board and that its internal investigation resulted from "the Company's purchase of a condominium for a purchase price of approximately $1.1 million" and "the Company's commitment to sponsor a sports tournament in the amount of $640,000," both of which "were undertaken by the Company's management without sufficient and appropriate consultation with or approval by the Board."

On November 15, 2021, Alfi disclosed it "received a letter from the staff of the [SEC] indicating that the Company, its affiliates and agents may possess documents and data relevant to an ongoing investigation being conducted by the staff of the SEC." Further, the Company should preserve documents that "relate or refer to the condominium or the sports tournament sponsorship identified in the Company's Current Report on Form 8-K filed on November 1, 2021, or financial reporting and disclosure controls, policies or procedures."

Finally, on November 16, 2021, Alfi filed a notice of its inability to timely file its quarterly report on Form 10-Q with the SEC for the quarter ended September 30, 2021. The stock now trades at just around $3.

If you purchased shares of Alfi, Inc. (ALF, ALFIW) stock or warrants pursuant to the Company's IPO or securities between May 4, 2021 and November 15, 2021, you have until January 31, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Alfi, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom